Navigation Links
Pennsylvania Hospital surgeon receives grant to develop molecular cardiac surgery
Date:11/28/2007

expression in animals other than rodents and mice.

The molecular cardiac surgical approach has an added advantage since genes are expressed only in the heart, enhancing the safety of this approach over all other available gene delivery methods. The preliminary success of molecular cardiac surgery opens the door to developing new treatments for a variety of heart muscle diseases causing heart failure.

A carrier called a vector is used to deliver the specially designed beneficial genes (transgenes). The most common vector is a virus that has been genetically altered. Viruses have evolved ways of delivering their genes to human cells in a pathogenic manner. Researchers have taken advantage of this capability by removing disease-causing genes from the virus and inserting therapeutic genes. The vector then discharges the therapeutic genes into the target cell. The new grant will enable Dr. Bridges to move beyond his work with marker genes and begin testing his findings using therapeutic genes in sheep with heart failure.

Dr. Bridges closely collaborates with Hansell Stedman, M.D., Associate Professor of Surgery at the University of Pennsylvania. Dr. Bridges and Dr. Stedman jointly have several U.S. and international patents for the efficient use of vectors in gene delivery to cardiac and skeletal muscle. Prior to their work, delivery techniques in common use typically resulted in one-to-two percent expression of therapeutic genes in the target cells. Dr. Bridges and Dr. Stedman generate successful delivery rates approaching 100 percent in both skeletal and cardiac muscle. In addition, their delivery methods enable safe removal of the delivery device once the therapeutic genes are delivered. This substantially reduces the risk of harm to other organs in the body.

"This grant will enable us to build on the advances my colleagues and I have been fortunate to achieve," says Dr. Bridges. "Molecular cardiac surgery offers genuine prom
'/>"/>

Contact: Lee-Ann Landis
landisl@uphs.upenn.edu
215-829-8043
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
2. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
3. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
4. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
5. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
6. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
7. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
8. Cardiologists and heart surgeons meet for Controversies and Advances conference
9. Rutgers Genetics receives $7.8 million for autism research
10. Herr receives Heinz Award for Technology, the Economy and Employment
11. UCI receives $5M from Edwards Lifesciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
(Date:12/5/2014)... 4, 2014 Increased emphasis on product ... new testing and inspection technologies. The convergence of ... a range of innovative test solutions. This trend ... Y, which is generally more inclined towards communication, ... development strategies of test equipment vendors will cater ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... brain, but they also leave behind in the bloodstream a ... the future to direct better treatment for schizophrenia and other ... study is among the first to use metabolomics -- the ... processes -- to look at a psychiatric disease and its ...
... Research Institute on Addictions (RIA) is investigating the “brain’s ... stress, stress-related behavior and anxiety. , A five-year, $1.7 ... is supporting this investigation. , “It is widely ... use and abuse marijuana is to relieve stress,?according to ...
... generators (dopaminergics) in brain cells has produced improvement in ... tests carried out with monkeys by the Navarra University ... at the Hospital and at the other Navarra University-based ... , The results have been published in the latest ...
Cached Biology News:Chemical maps hint at drug's effects on schizophrenia 2Chemical maps hint at drug's effects on schizophrenia 3Implanting dopamine generators in brain cells obtains improvement in Parkinson's in monkeys 2Implanting dopamine generators in brain cells obtains improvement in Parkinson's in monkeys 3
(Date:12/24/2014)... , Dec. 23, 2014 Vermillion, ... focused on gynecologic disease, announced today that investors ... , Birchview Fund LLC and several Vermillion directors ... unregistered shares of Vermillion,s common stock and warrants ... in a private placement.  Under ...
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences ... Decipher Prostate Cancer Classifier, a genomic test for prostate ... node-negative, high-risk men managed by radical prostatectomy without adjuvant ... prostatectomy is relatively uncommon, using tumor genomics to identify ... metastatic disease is an important advance. The study has ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... BioMS Medical Corp (TSX: MS), a leading developer in the ... Stroud, Vice President Regulatory Affairs, will present at the Canadian ... TITLE: "Dirucotide: ... Thursday June 4th ...
... of integrating and sustaining positive change, increasing wellnessWASHINGTON, ... stress can wreak havoc on a body,s systems. ... change paradigm helps individuals cultivate greater wellness, make ... of life in the face of challenges.The approach, ...
... presenting at the Global Crop Protection Summit and exposition on 15-17th ... ... London, UK (PRWeb UK) - Pira International and ... Protection Summit in Edinburgh, Scotland on 15 - 17 September 2009. ...
Cached Biology Technology:BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences 2Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress 2Call for papers for Pira International's Global Crop Protection Summit 2009 2
... Security ChemStation is a ... application for data acquisition, ... searching and reporting, addressing ... data security, integrity, and ...
... These handy dispensers save ... glasses, wipers, hats, and other ... benchtop storage bins for small ... and manufacturing. Clear acrylic. Open-slot ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Soil Nematode microRNA Microarray contains all ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: